Roche announces positive Phase II petrelintide results

Roche has reported positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity. The announcement, made on 5 March 2026, positions petrelintide as a promising candidate in the increasingly competitive obesity therapeutics landscape.\n Petrelintide was acquired by Roche through its acquisition of Carmot Therapeutics in late 2023, which brought a portfolio of incretin and amylin-based candidates into Roche's pipeline. The amylin class works through a distinct mechanism from GLP-1 receptor agonists, offering potential for combination therapy or use in patients who do not respond adequately to GLP-1-based treatments.

What is petrelintide?

Petrelintide is a synthetic amylin analog. Amylin (also known as islet amyloid polypeptide, or IAPP) is a hormone co-secreted with insulin by pancreatic beta cells. It promotes satiety, slows gastric emptying, and reduces postprandial glucagon secretion — effects that make it an attractive target for obesity and metabolic disease.

For a detailed profile of petrelintide's mechanism, evidence, and research context, see our petrelintide compound profile.

The amylin agonist landscape

Petrelintide enters a competitive but still emerging field. The most advanced amylin-based therapeutic is cagrilintide, Novo Nordisk's amylin analog, which is being developed both as a standalone agent and in combination with semaglutide as CagriSema. CagriSema recently reported 22.7% weight loss in the REDEFINE-1 Phase III trial.

Roche's petrelintide results suggest the amylin class may have multiple viable candidates, potentially expanding treatment options. The distinct mechanism of amylin agonists — acting independently of GLP-1 pathways — also creates opportunities for combination approaches.

Implications for peptide research

The advancement of petrelintide is significant for the peptide research community for several reasons:

  1. Mechanistic diversity: Amylin agonists offer a pathway distinct from GLP-1, GIP, and glucagon receptor agonists, broadening the toolkit for metabolic research.

  2. Combination potential: Early data suggests amylin agonists may be effective in combination with incretin therapies, potentially achieving greater weight loss than monotherapy.

  3. Competitive pipeline: With both Novo Nordisk (cagrilintide) and Roche (petrelintide) investing in amylin analogs, the class is likely to receive significant research attention in the coming years.

UK context

Petrelintide remains an investigational compound and is not approved by the MHRA or any other regulatory body. As a research peptide, it is not a licensed medicine in the UK. Researchers should note that amylin analogs in clinical development are subject to standard regulatory oversight, and any use outside of approved clinical trials would fall under the same restrictions as other unlicensed peptides.

Looking ahead

Roche indicated that petrelintide will advance to Phase III trials. Key questions for future data include:

  • Whether petrelintide's weight loss efficacy is competitive with or complementary to GLP-1-based therapies
  • The safety profile, particularly regarding amylin-specific concerns such as amyloid formation
  • Whether combination data with GLP-1 agonists will be generated

The obesity peptide landscape continues to evolve rapidly. With GLP-1 agonists (semaglutide, tirzepatide), triple agonists (retatrutide), oral GLP-1s (orforglipron, danuglipron), and now multiple amylin analogs in development, 2026 is shaping up to be a pivotal year for metabolic peptide therapeutics.

This article is for research and educational purposes only. Petrelintide is an investigational compound and is not approved for human use. Nothing in this article constitutes medical advice.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.